David D. Meek

David D. Meek (chief executive) discloses dealings in 4 companies, chiefly uniQure N.V., Mirati Therapeutics, Inc. and Entasis Therapeutics Holdings Inc. The record holds 28 filings, for trades running from 3 March 2016 to 20 June 2025.

Sales make up the whole of the open-market record (10 sales, €449k). The rest of the record consists of 15 share grants. 2025 to date brings no purchases and 1 sale.

The record was last updated on 24 June 2025 with an open-market sale (€27k) in uniQure N.V. The median gap between a trade and its publication by SEC (Form 4) is 3 days. Section 16 rules allow two business days to file each Form 4. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.